SUN Farmaceutica DO Brazil Ltda Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: SUN Farmaceutica DO Brazil Ltda Pharmaceutical Import Records from India — 2 Products, $350.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

SUN Farmaceutica DO Brazil Ltda — Pharmaceutical Importer Profile (2026) | 2 Products, $350.0K Trade | TransData Nexus

SUN Farmaceutica DO Brazil Ltda

Pharmaceutical Importer · Brazil · Advanced Oncology Focus · $350.0K Total Trade · DGFT Verified

SUN Farmaceutica DO Brazil Ltda is a pharmaceutical importer based in Brazil with a total trade value of $350.0K across 2 products in 1 therapeutic categories. Based on 7 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. SUN Farmaceutica DO Brazil Ltda sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

SUN Farmaceutica DO Brazil Ltda — Import Portfolio & Supplier Network

SUN Farmaceutica DO Brazil Ltda import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to SUN Farmaceutica DO Brazil Ltda?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$2.7M	178	100.0%

SUN Farmaceutica DO Brazil Ltda sources from 1 verified Indian supplier across 130 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pantasun i.v INJ (pantoprazole)	$323.4K	7
Capecitabina 500MG tablets Each	$200.0K	4
Anya tablets USP 1 MG (anastrozole)	$150.0K	3
Nidhi capsules 150MG (Each capsule contains nintedanib equivalent to 150MG) [1155 Pack x 6x10] batch no. haf0387a mfg	$150.0K	3
Abiraterone tablets USP 250MG Each	$100.0K	2
Pantasun i.v INJ (pantoprazole) batch	$100.0K	2
Gulshen TAB 300 MG 3x10b braz (ursodeoxycholic acid )	$100.0K	2
Gulshen TAB 300 MG 3x10b braz ursodeoxycholic acid Pack box3x10s	$100.0K	2
Zomi Each contains bortezomib Pack	$82.2K	2
Pantasun i.v INJ ( pentoprazole) (Pack:01x01)	$55.8K	3
Abiraterone tabelets USP 250MG Pack	$50.0K	1
Octride 100 INJ. (octreotide injection	$50.0K	1
Abiraterone tablets USP 250MG	$50.0K	1
Pantasun i.v. INJ. batch : had4025a	$50.0K	1
Pantasun i.v. INJ. batch:had2577a	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Anastrozole	Advanced Oncology	$250.0K	5	0.2%	12
2	Bortezomib	Advanced Oncology	$100.0K	2	0.5%	8

SUN Farmaceutica DO Brazil Ltda imports 2 pharmaceutical products across 1 categories into Brazil totaling $350.0K.

SUN Farmaceutica DO Brazil Ltda — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

SUN Farmaceutica do Brasil Ltda, operating under the trade name Sun Pharma, is a Brazilian pharmaceutical importer and wholesaler specializing in the distribution of finished pharmaceutical formulations. Established on April 25, 2002, and headquartered in Goiânia, Goiás, the company plays a pivotal role in Brazil's pharmaceutical supply chain by sourcing and distributing a diverse range of pharmaceutical products. (infoinvest.com.br)

The company is a subsidiary of Sun Pharmaceutical Industries Limited, a leading global pharmaceutical manufacturer based in India. This affiliation underscores Sun Pharma's strategic importance in facilitating the import and distribution of Sun Pharmaceutical's products within the Brazilian market. Additionally, Sun Pharma operates two active branches: one in Rio de Janeiro, established on August 13, 2021, and another in Barueri, São Paulo, established on January 31, 2011. (cnpj.biz)

2Distribution Network

Sun Pharma's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across Brazil. The company's primary warehouse is located in Goiânia, Goiás, serving as the central hub for operations. To enhance its reach and operational efficiency, Sun Pharma has established additional facilities in Rio de Janeiro and São Paulo, thereby expanding its logistical capabilities and geographic coverage. (infoinvest.com.br)

3Industry Role

In Brazil's pharmaceutical supply chain, Sun Pharma functions as a primary wholesaler and importer. The company is responsible for sourcing finished pharmaceutical formulations from international suppliers, particularly from India, and distributing these products to various stakeholders within the Brazilian healthcare system. This role is crucial in ensuring the availability of a wide range of pharmaceutical products to meet the diverse needs of the Brazilian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — SUN Farmaceutica DO Brazil Ltda

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sun Pharma's sourcing strategy exhibits a high degree of concentration, with a total import value of $350,000 USD from India across seven shipments, primarily consisting of two products: Anastrozole and Bortezomib. This focused approach indicates a strategic choice to concentrate on specific therapeutic areas, potentially leveraging the expertise and cost advantages offered by Indian manufacturers. The consistent sourcing from a single supplier, Sun Pharmaceutical Industries Limited, suggests a stable and reliable relationship, which is beneficial for maintaining product quality and supply chain consistency.

2Supply Chain Resilience

The resilience of Sun Pharma's supply chain is closely tied to its reliance on Sun Pharmaceutical Industries Limited as the sole supplier. While this single-source dependency streamlines operations and ensures consistency, it also exposes the company to risks associated with supply disruptions from this supplier. The limited diversification in formulations imported may further impact the company's ability to adapt to changing market demands or supply chain challenges. To enhance resilience, exploring additional suppliers and diversifying the product portfolio could be strategic considerations.

Strategic Implications

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the National Health Surveillance Agency (ANVISA) is the primary regulatory authority overseeing the pharmaceutical sector. ANVISA is responsible for ensuring the safety, efficacy, and quality of pharmaceutical products through rigorous regulatory frameworks. Key legislation governing pharmaceutical imports includes the Brazilian Health Regulatory Agency Act and the National Health Surveillance Agency Act, which outline the procedures for product registration, importation, and distribution. The marketing authorization pathway for Indian generics involves obtaining ANVISA approval, which requires comprehensive documentation, including clinical trial data and manufacturing process details, to demonstrate bioequivalence and compliance with Brazilian standards.

2Import Licensing & GMP

Import licensing in Brazil is a critical component of the pharmaceutical regulatory process. Companies like Sun Pharma must obtain an import license from ANVISA, which involves submitting detailed information about the products, including their composition, intended use, and manufacturing processes. Good Manufacturing Practice (GMP) certification is mandatory for all pharmaceutical products imported into Brazil. ANVISA recognizes GMP certifications from reputable international bodies, such as the European Medicines Agency (EMA), the World Health Organization (WHO), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). This recognition facilitates the importation of high-quality generics from countries like India, provided they meet the stipulated GMP standards.

SUN Farmaceutica DO Brazil Ltda — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sun Pharma's focus on importing Anastrozole and Bortezomib aligns with the growing demand for advanced oncology treatments in Brazil. Anastrozole, a non-steroidal aromatase inhibitor, is widely used in the treatment of breast cancer, while Bortezomib, a proteasome inhibitor, is utilized in the management of multiple myeloma. The decision to import these specific therapeutic areas is driven by the increasing prevalence of cancer in Brazil and the need for effective treatment options. By concentrating on these high-demand products, Sun Pharma positions itself as a key player in addressing critical healthcare needs within the Brazilian oncology sector.

2Sourcing Profile

Sun Pharma's sourcing strategy is centered on importing generic drugs from India, focusing on formulations that have demonstrated bioequivalence and compliance with international GMP standards. This approach ensures access to cost-effective and high-quality pharmaceutical products. India's well-established pharmaceutical manufacturing sector, with its robust regulatory oversight and adherence to global quality standards, makes it an ideal sourcing partner for Sun Pharma. The company's procurement strategy emphasizes reliability, quality, and regulatory compliance to meet the stringent requirements of the Brazilian market.

3Market Positioning

Seller's Guide — How to Become a Supplier to SUN Farmaceutica DO Brazil Ltda

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Sun Pharma, especially if they can offer products that meet ANVISA's regulatory standards and demonstrate bioequivalence to existing treatments. Gaps in Sun Pharma's current sourcing include potential expansion into other therapeutic areas and the introduction of innovative formulations. Indian exporters can explore these opportunities by aligning their product offerings with Sun Pharma's strategic focus and the evolving healthcare needs of the Brazilian market.

2Requirements & Qualifications

Indian exporters aiming to supply Sun Pharma and the broader Brazilian market must ensure their products are registered with ANVISA and comply with Brazilian GMP standards. This includes obtaining necessary certifications, conducting required clinical studies, and adhering to labeling and packaging regulations. Additionally, exporters should be prepared to provide comprehensive documentation to demonstrate product quality, safety, and efficacy, facilitating a smoother entry into the Brazilian pharmaceutical market.

3How to Approach

Frequently Asked Questions — SUN Farmaceutica DO Brazil Ltda

What products does SUN Farmaceutica DO Brazil Ltda import from India?

SUN Farmaceutica DO Brazil Ltda imports 2 pharmaceutical products across 1 categories. Top imports: Anastrozole ($250.0K), Bortezomib ($100.0K).

Who supplies pharmaceuticals to SUN Farmaceutica DO Brazil Ltda from India?

SUN Farmaceutica DO Brazil Ltda sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $2.7M).

What is SUN Farmaceutica DO Brazil Ltda's total pharmaceutical import value?

SUN Farmaceutica DO Brazil Ltda's total pharmaceutical import value from India is $350.0K, based on 7 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does SUN Farmaceutica DO Brazil Ltda focus on?

SUN Farmaceutica DO Brazil Ltda imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full SUN Farmaceutica DO Brazil Ltda Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.